Up To $49M Private Placement Fuels CalciMedica's Pulmonary Hypertension Program
CALC has more than doubled off its 52-week low of $0.461 on light trading volume (0.3× avg).
Summary
CalciMedica announced a private placement financing of up to $49 million. This substantial capital infusion, more than three times the company's current market cap, provides a cash runway into the second half of 2027. The proceeds are earmarked to advance the Phase 1b Auxora study in pulmonary hypertension and support CM5480 IND clearance. This financing significantly de-risks the company's operations and enables critical pipeline development. Data from the Auxora PAH study and CM5480 IND clearance are expected mid-2027.
At the time of this announcement, CALC was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $0.46 to $7.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.